Seth S Martin1, Michael J Blaha2, Evan D Muse3, Atif N Qasim4, Muredach P Reilly5, Roger S Blumenthal2, Khurram Nasir6, Michael H Criqui7, Robyn L McClelland8, Jan M Hughes-Austin7, Matthew A Allison7. 1. Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA. Electronic address: smart100@jhmi.edu. 2. Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA. 3. Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA; Scripps Translational Science Institute, La Jolla, CA, USA. 4. Division of Cardiology, University of California San Francisco, San Francisco, CA, USA. 5. Division of Cardiology, University of Pennsylvania Medical Center, Philadelphia, PA, USA. 6. Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA; Center for Prevention and Wellness Research, Baptist Health Medical Group, Miami Beach, FL, USA; Miami Cardiovascular Institute (MCVI), Baptist Health South Florida, Miami, FL, USA; Department of Medicine, Herbert Wertheim College of Medicine, University Park, FL, USA; Department of Epidemiology, Robert Stempel College of Public Health, Florida International University, Miami, FL, USA. 7. Division of Preventive Medicine, University of California, San Diego, La Jolla, CA, USA. 8. Department of Biostatistics, University of Washington, Seattle, WA, USA.
Abstract
OBJECTIVE: Higher serum leptin levels have been associated with a modestly higher incidence of cardiovascular disease in studies involving mostly Caucasian men. We aimed to assess the hypothesis that higher baseline levels of serum leptin are associated with higher risk of future cardiovascular disease in a diverse cohort. METHODS: The Multi-Ethnic Study of Atherosclerosis (MESA) is a modern, community-based, ethnically-diverse, and sex-balanced prospective cohort study of US adults free from cardiovascular disease. Serum leptin was measured in an ancillary study in 2002-2005. This analysis included 1905 MESA participants with baseline leptin and incident cardiovascular event data. Leptin levels were modeled as a log-transformed continuous variable and multivariable-adjusted Cox regression was performed for the primary outcome of hard cardiovascular disease, including coronary heart disease and stroke. RESULTS: The median follow-up was 7.6 years (25th-75th 7.1-8.3) with 7051 and 6738 person-years of follow-up in women and men. A hard cardiovascular disease event occurred in 47 women and 63 men. The age- and ethnicity-adjusted hazard ratio estimates for a 1 standard deviation increase in ln(leptin) were 1.16 in women (95% CI 0.78-1.73, p = 0.46) and 0.91 (95% CI 0.69-1.20, p = 0.51) in men. Pooling sexes, and adjusting for sex in addition to age and ethnicity, estimates were 0.98 (95% CI 0.78-1.23, p = 0.89). With additional adjustment for cardiovascular risk factors, the results remained nonsignificant: 0.87 (95% CI 0.68-1.11, p = 0.26). CONCLUSION: In conclusion, in a modern, US prospective cohort study of multi-ethnic women and men of multi-ethnic backgrounds, leptin levels are not associated with incident cardiovascular events.
OBJECTIVE: Higher serum leptin levels have been associated with a modestly higher incidence of cardiovascular disease in studies involving mostly Caucasian men. We aimed to assess the hypothesis that higher baseline levels of serum leptin are associated with higher risk of future cardiovascular disease in a diverse cohort. METHODS: The Multi-Ethnic Study of Atherosclerosis (MESA) is a modern, community-based, ethnically-diverse, and sex-balanced prospective cohort study of US adults free from cardiovascular disease. Serum leptin was measured in an ancillary study in 2002-2005. This analysis included 1905 MESAparticipants with baseline leptin and incident cardiovascular event data. Leptin levels were modeled as a log-transformed continuous variable and multivariable-adjusted Cox regression was performed for the primary outcome of hard cardiovascular disease, including coronary heart disease and stroke. RESULTS: The median follow-up was 7.6 years (25th-75th 7.1-8.3) with 7051 and 6738 person-years of follow-up in women and men. A hard cardiovascular disease event occurred in 47 women and 63 men. The age- and ethnicity-adjusted hazard ratio estimates for a 1 standard deviation increase in ln(leptin) were 1.16 in women (95% CI 0.78-1.73, p = 0.46) and 0.91 (95% CI 0.69-1.20, p = 0.51) in men. Pooling sexes, and adjusting for sex in addition to age and ethnicity, estimates were 0.98 (95% CI 0.78-1.23, p = 0.89). With additional adjustment for cardiovascular risk factors, the results remained nonsignificant: 0.87 (95% CI 0.68-1.11, p = 0.26). CONCLUSION: In conclusion, in a modern, US prospective cohort study of multi-ethnic women and men of multi-ethnic backgrounds, leptin levels are not associated with incident cardiovascular events.
Authors: David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli Journal: Circulation Date: 2013-11-12 Impact factor: 29.690
Authors: Paul J W H Kappelle; Robin P F Dullaart; André P van Beek; Hans L Hillege; Bruce H R Wolffenbuttel Journal: Eur J Intern Med Date: 2012-07-20 Impact factor: 4.487
Authors: Alessandro Ble; B Gwen Windham; Stefania Bandinelli; Dennis D Taub; Stefano Volpato; Benedetta Bartali; Russell P Tracy; Jack M Guralnik; Luigi Ferrucci Journal: Am J Cardiol Date: 2005-10-01 Impact factor: 2.778
Authors: Muredach P Reilly; Nayyar Iqbal; Mark Schutta; Megan L Wolfe; Monique Scally; A Russell Localio; Daniel J Rader; Stephen E Kimmel Journal: J Clin Endocrinol Metab Date: 2004-08 Impact factor: 5.958
Authors: Matthew A Allison; David A Bluemke; Robyn McClelland; Mary Cushman; Michael H Criqui; Joseph F Polak; Joao A Lima Journal: Am J Cardiol Date: 2013-05-24 Impact factor: 2.778
Authors: Robert Detrano; Alan D Guerci; J Jeffrey Carr; Diane E Bild; Gregory Burke; Aaron R Folsom; Kiang Liu; Steven Shea; Moyses Szklo; David A Bluemke; Daniel H O'Leary; Russell Tracy; Karol Watson; Nathan D Wong; Richard A Kronmal Journal: N Engl J Med Date: 2008-03-27 Impact factor: 91.245
Authors: Atif Qasim; Nehal N Mehta; Mahlet G Tadesse; Megan L Wolfe; Thomas Rhodes; Cynthia Girman; Muredach P Reilly Journal: J Am Coll Cardiol Date: 2008-07-15 Impact factor: 24.094
Authors: Aurelian Bidulescu; Jiankang Liu; Zhimin Chen; Demarc A Hickson; Solomon K Musani; Tandaw E Samdarshi; Ervin R Fox; Herman A Taylor; Gary H Gibbons Journal: Front Public Health Date: 2013-05-24
Authors: Mohamed I Saad; Taha M Abdelkhalek; Moustafa M Saleh; Maher A Kamel; Mina Youssef; Shady H Tawfik; Helena Dominguez Journal: Endocrine Date: 2015-08-14 Impact factor: 3.633
Authors: Jennifer E Ho; Elizabeth L McCabe; Thomas J Wang; Martin G Larson; Daniel Levy; Connie Tsao; Jayashri Aragam; Gary F Mitchell; Emelia J Benjamin; Ramachandran S Vasan; Susan Cheng Journal: Circ Heart Fail Date: 2017-05 Impact factor: 8.790
Authors: Jessica B Kendrick; Leila Zelnick; Michel B Chonchol; David Siscovick; Andrew N Hoofnagle; Joachim H Ix; Mark Sarnak; Michael G Shlipak; Bryan Kestenbaum; Ian H de Boer Journal: Am J Nephrol Date: 2016-12-10 Impact factor: 3.754
Authors: Michael J Ryan; T Taylor Coleman; Jennifer M Sasser; Katarina M Pittman; Michael W Hankins; David E Stec Journal: Am J Physiol Regul Integr Comp Physiol Date: 2016-03-02 Impact factor: 3.619
Authors: Susan A Everson-Rose; Cari J Clark; Qi Wang; Hongfei Guo; Peter Mancuso; Howard M Kravitz; Joyce T Bromberger Journal: Psychoneuroendocrinology Date: 2018-07-05 Impact factor: 4.905